---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-228145"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2022-08-24T23:59:59+00:00"
generated_at: "2026-06-23T21:42:30.557423+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apellis reports 24-month Phase 3 data: pegcetacoplan shows increasing efficacy in GA

## Summary
- At 24 months, monthly pegcetacoplan reduced GA lesion growth 19% in DERBY (p=0.0004) and 22% in OAKS (p<0.0001) vs sham.
- Between months 18-24, treatment effect accelerated: DERBY monthly 36% (p<0.0001), OAKS monthly 24% (p=0.0080) reduction.
- Safety profile consistent; infectious endophthalmitis rate 0.034% per injection, no occlusive vasculitis or retinitis over 24 months.
- US PDUFA target action date Nov 26, 2022; EU marketing authorization application planned by end of 2022.
- Key secondary visual function endpoints showed no clinically meaningful difference at 24 months, attributed to endpoint limitations.

## SEC filing metadata
- accession: 0001193125-22-228145
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2022-08-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312522228145/0001193125-22-228145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312522228145/d305749d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-228145
- JSON: https://secwatch.observer/filing/0001193125-22-228145.json
- Plain text: https://secwatch.observer/filing/0001193125-22-228145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.